Natriuretic peptides in the diagnosis and management of heart failure

Felker, G. Michael; Petersen, John W.; Mark, Daniel B.
September 2006
CMAJ: Canadian Medical Association Journal;9/12/2006, Vol. 175 Issue 6, p611
Academic Journal
The natriuretic peptides are a family of related hormones that play a crucial role in cardiovascular homeostasis. They have recently emerged as potentially important clinical markers in heart failure. Recent data have suggested an important role for these markers in establishing the diagnosis of heart failure in patients with unexplained dyspnea in both acute care and ambulatory settings. Other clinical uses of the natriuretic peptides, such as screening for asymptomatic ventricular dysfunction, establishing prognosis or guiding titration of drug therapy, are under investigation but have not yet sufficiently been validated for widespread clinical use.


Related Articles

  • Natriuretic peptides as a prognostic marker and therapeutic target in heart failure. Wright, G. A.; Sfruthers, A. D. // Heart;Feb2006, Vol. 92 Issue 2, p149 

    The article focuses on the growing significance on the use and application of B-type natriuretic peptides (BNP) as a prognostic marker and therapeutic target in heart failure. The author points out that chronic heart failure still have high rates of mortality and hospital readmission despite...

  • Commentary. Wyer, Peter C. // Evidence Based Medicine;Apr2006, Vol. 11 Issue 2, p58 

    The article comments on a study on the use of medical history, physical examination and routine tests for diagnosing heart failure in dyspnea. Initial treatments for dyspnea differ and are started before definitive test results are known. Type B natriuretic peptide level is associated with heart...

  • BNP to Guide Treatment of Heart Failure. Kuritzky, Louis // Clinical Oncology Alert;Apr2009 Supplement, Vol. 14 Issue 4, p8 

    The article discusses research being done on guiding the treatment of heart failure through examining brain natriuretic peptide (BNP). It references a study by M. Pfisterer, et al, published in the 2008 issue of the "Journal of the American Medical Association." BNP is said to be useful to...

  • Effect of Short-Term Maximal Exercise on BNP Plasma Levels in Healthy Individuals. Krupička, J.; Janota, T.; Kasalová, Z.; Hradec, J. // Physiological Research;2010, Vol. 59 Issue 4, p625 

    Many studies documented the relationship between elevated plasma concentrations of natriuretic peptides and cardiovascular diseases, especially heart failure. However, it is still uncertain whether physical exercise leads to a significant release of natriuretic peptide in healthy subjects. The...

  • Cardiovascular disease: PDE9A inhibition mends broken hearts. Bray, Natasha // Nature Reviews Drug Discovery;May2015, Vol. 14 Issue 5, p310 

    The article discusses research on the possible effectivity of phosphodiesteras 9A (PDE9A) inhibition in the treatment of heart failure with preserved ejection fraction (HFPEF). It references the study "Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease" by...

  • B-Type Natriuretic Peptide – A Window to the Heart. Baughman, Kenneth L. // New England Journal of Medicine;7/18/2002, Vol. 347 Issue 3, p158 

    The article presents the author's views about a study on B-type natriuretic peptide. According to the author, the study confirms the importance of B-type natriuretic peptide in the diagnosis of congestive heart failure. The author says that cardiologists and internists may now have a tool which...

  • Diagnostic value of a rapid test for B-type natriuretic peptide in patients presenting with acute dyspnoe: effect of age and gender. Wold Knudsen, Cathrine; Sigurd Riis, Jon; Finsen, Alexandra V.; Eikvar, Lars; Müller, Carl; Westheim, Arne; Omland, Torbjørn // European Journal of Heart Failure;Jan2004, Vol. 6 Issue 1, p55 

    Background: B-type natriuretic peptide (BNP) measurements are useful for diagnosing congestive heart failure (CHF) in patients presenting to the Emergency Department with acute dyspnoe. Whether the diagnostic accuracy of BNP is affected by the age and gender of the patients remains unknown....

  • N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Nielsen, Lene Svendstrup; Svanegaard, Jens; Anders Klitgaard, Niels; Egeblad, Henrik // European Journal of Heart Failure;Jan2004, Vol. 6 Issue 1, p63 

    Aim: Evaluation of N-terminal pro-brain natriuretic peptide (NT-proBNP) to confirm or disprove heart failure in community patients complaining of dyspnoea. Methods and results: General practitioners referred 345 consecutive patients complaining of dyspnoea to our hospital-based clinic, where a...

  • Interpretation and Use of Natriuretic Peptides in Non-Cnngestive Heart Fillure Settings. Shih-Hung Tsai; Yen-Yue Lin; Shi-Jye Chu; Ching-Wang Hsu; Shu-Meng Cheng // Yonsei Medical Journal;3/1/2010, Vol. 51 Issue 2, p151 

    Natriuretic peptides (NPs) have been found to be useful markers in differentiating acute dyspneic patients presenting to the emergency department (ED) and emerged as potent prognostic markers for patients with congestive heart failure (CHF). The best-established and widely used clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics